SILO vs. SNPX, SNGX, CELZ, AIMD, ADIL, NSTGQ, HEPA, SONX, HOTH, and ENVB
Should you be buying Silo Pharma stock or one of its competitors? The main competitors of Silo Pharma include Synaptogenix (SNPX), Soligenix (SNGX), Creative Medical Technology (CELZ), Ainos (AIMD), Adial Pharmaceuticals (ADIL), NanoString Technologies (NSTGQ), Hepion Pharmaceuticals (HEPA), Sonendo (SONX), Hoth Therapeutics (HOTH), and Enveric Biosciences (ENVB). These companies are all part of the "medical" sector.
Silo Pharma (NASDAQ:SILO) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.
Synaptogenix has a net margin of 0.00% compared to Silo Pharma's net margin of -4,992.30%. Synaptogenix's return on equity of -18.51% beat Silo Pharma's return on equity.
Silo Pharma and Synaptogenix both received 1 outperform votes by MarketBeat users. However, 100.00% of users gave Silo Pharma an outperform vote while only 50.00% of users gave Synaptogenix an outperform vote.
Silo Pharma has higher revenue and earnings than Synaptogenix.
Silo Pharma currently has a consensus target price of $10.00, suggesting a potential upside of 420.83%. Given Silo Pharma's higher possible upside, analysts clearly believe Silo Pharma is more favorable than Synaptogenix.
In the previous week, Silo Pharma had 1 more articles in the media than Synaptogenix. MarketBeat recorded 4 mentions for Silo Pharma and 3 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.63 beat Silo Pharma's score of 0.00 indicating that Synaptogenix is being referred to more favorably in the news media.
Silo Pharma has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
5.6% of Silo Pharma shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 5.6% of Silo Pharma shares are held by company insiders. Comparatively, 4.3% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Silo Pharma beats Synaptogenix on 7 of the 13 factors compared between the two stocks.
Get Silo Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SILO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SILO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silo Pharma Competitors List
Related Companies and Tools
